Literature DB >> 22475482

Human peroxiredoxin 1 modulates TGF-β1-induced epithelial-mesenchymal transition through its peroxidase activity.

Bin Ha1, Eun-Kyung Kim, Ji-Hee Kim, Hae Na Lee, Kyun Oh Lee, Sang Yeol Lee, Ho Hee Jang.   

Abstract

The epithelial-to-mesenchymal transition (EMT), which is induced by transforming growth factor-β1 (TGF-β1), is an important event that allows cancer cells to obtain invasive and metastatic characteristics. Although human peroxiredoxin 1 (hPrx1) has been implicated in tumor progression (e.g., invasion and metastasis), little is known about the role of hPrx1 in the EMT process during tumorigenesis. Here, we investigated the regulatory effect of hPrx1 during TGF-β1-induced EMT in A549 lung adenocarcinoma cells. We observed that high hPrx1 levels downregulated E-cadherin expression, and low hPrx1 levels upregulated E-cadherin expression, suggesting that the hPrx1 level may be correlated with EMT. Knockdown of hPrx1 significantly inhibited TGF-β1-induced EMT and cell migration, whereas hPrx1 overexpression enhanced TGF-β1-induced EMT and cell migration. In contrast to wild-type hPrx1, a peroxidase-inactive hPrx1 mutant (hPrx1-C51S) resulted in markedly increased E-cadherin expression. Moreover, hPrx1 regulated the expression of two E-cadherin transcriptional repressors, Snail and Slug. These findings provide new insight into the role of hPrx1 in regulating TGF-β1-induced EMT.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22475482     DOI: 10.1016/j.bbrc.2012.03.103

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

Review 1.  The sulfiredoxin-peroxiredoxin (Srx-Prx) axis in cell signal transduction and cancer development.

Authors:  Murli Mishra; Hong Jiang; Lisha Wu; Hedy A Chawsheen; Qiou Wei
Journal:  Cancer Lett       Date:  2015-07-10       Impact factor: 8.679

2.  sFRP1 inhibits epithelial-mesenchymal transition in A549 human lung adenocarcinoma cell line.

Authors:  Jin Ren; Rui Wang; Guichun Huang; Haizhu Song; Yitian Chen; Longbang Chen
Journal:  Cancer Biother Radiopharm       Date:  2013-06-26       Impact factor: 3.099

3.  Aberrant expression of peroxiredoxin 1 and its clinical implications in liver cancer.

Authors:  Yu-Lin Sun; Jian-Qiang Cai; Fang Liu; Xin-Yu Bi; Lan-Ping Zhou; Xiao-Hang Zhao
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

Review 4.  The Multifaceted Impact of Peroxiredoxins on Aging and Disease.

Authors:  Svetlana N Radyuk; William C Orr
Journal:  Antioxid Redox Signal       Date:  2018-01-17       Impact factor: 8.401

5.  Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma.

Authors:  Qi-Kai Sun; Jian-Yu Zhu; Wei Wang; Yang Lv; Hang-Cheng Zhou; Ji-Hai Yu; Ge-Liang Xu; Jin-Liang Ma; Wen Zhong; Wei-Dong Jia
Journal:  Med Oncol       Date:  2013-12-03       Impact factor: 3.064

6.  Akt-mediated transforming growth factor-β1-induced epithelial-mesenchymal transition in cultured human esophageal squamous cancer cells.

Authors:  X Xuan; Q Zeng; Y Li; Y Gao; F Wang; H Zhang; Z Wang; H He; S Li
Journal:  Cancer Gene Ther       Date:  2014-05-30       Impact factor: 5.987

7.  The role of peroxiredoxins in cancer.

Authors:  Arianna Nicolussi; Sonia D'Inzeo; Carlo Capalbo; Giuseppe Giannini; Anna Coppa
Journal:  Mol Clin Oncol       Date:  2017-01-10

8.  High Expression of Peroxiredoxin 1 Is Associated with Epithelial-Mesenchymal Transition Marker and Poor Prognosis in Gastric Cancer.

Authors:  Wei Yu; Jing Wu; Zhong-Liang Ning; Qiao-Yu Liu; Rui-Liang Quan
Journal:  Med Sci Monit       Date:  2018-04-15

Review 9.  Peroxiredoxin 1 - an antioxidant enzyme in cancer.

Authors:  Chenbo Ding; Xiaobo Fan; Guoqiu Wu
Journal:  J Cell Mol Med       Date:  2016-09-21       Impact factor: 5.310

10.  Peroxiredoxin 1 promotes invasion and migration by regulating epithelial-to-mesenchymal transition during oral carcinogenesis.

Authors:  Wenwen Niu; Min Zhang; Hui Chen; Chunxiao Wang; Ni Shi; Xinying Jing; Lihua Ge; Tong Chen; Xiaofei Tang
Journal:  Oncotarget       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.